Quantum BioPharma Highlights Lucid-MS and unbuzzd™ Growth Opportunities on BioMedWire Podcast

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS, and its commercial product unbuzzd™. Durkacz highlighted that Lucid-MS targets mobility loss associated with multiple sclerosis by addressing nerve damage, an unmet need in current treatments. The company plans to initiate a Phase 2 clinical trial for Lucid-MS, the first study in multiple sclerosis patients following Phase 1 testing in healthy volunteers.

In addition to Lucid-MS, Durkacz discussed unbuzzd™, a product designed to accelerate blood alcohol metabolism and currently available in the U.S. market. Quantum BioPharma retains a 19.84% ownership stake in Unbuzzd Wellness Inc., which markets unbuzzd™, and is entitled to royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. The company also retains full rights to develop similar products for pharmaceutical and medical uses.

The podcast appearance underscores Quantum BioPharma's dual focus on innovative therapies for neurodegenerative diseases and commercial wellness products. The upcoming Phase 2 trial for Lucid-MS represents a significant milestone, as it will provide the first clinical data on the drug's efficacy in multiple sclerosis patients. Preclinical models have shown Lucid-MS can prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.

Quantum BioPharma's strategy includes leveraging its subsidiary, Lucid Psycheceuticals Inc., for research and development of Lucid-MS. The company's pipeline also addresses alcohol misuse disorders through unbuzzd™ and potential pharmaceutical formulations. The royalty structure with Unbuzzd Wellness Inc. provides a recurring revenue stream that could support further research and development.

Investors and stakeholders can access the full press release and additional information through the company's newsroom at https://ibn.fm/QNTM. The BioMedWire Podcast episode offers insights into Quantum BioPharma's growth opportunities and the potential impact of its drug candidates on patients with multiple sclerosis and alcohol metabolism issues.

Forward-looking statements in the release are subject to risks and uncertainties, including those described in the company's filings with the SEC. Quantum BioPharma undertakes no duty to update these statements unless required by law.